Premium
Immunosuppression with Tacrolimus Improved Reproductive Outcome of Women with Repeated Implantation Failure and Elevated Peripheral Blood Th1/Th2 Cell Ratios
Author(s) -
Nakagawa Koji,
KwakKim Joanne,
Ota Kuniaki,
Kuroda Keiji,
Hisano Michi,
Sugiyama Rikikazu,
Yamaguchi Koushi
Publication year - 2015
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.12338
Subject(s) - tacrolimus , medicine , immunosuppression , implantation failure , pregnancy , prospective cohort study , gastroenterology , miscarriage , transplantation , infertility , biology , genetics
Problem We evaluated the clinical efficacy of immunosuppressive treatment with tacrolimus for repeated implantation failure ( RIF ) patients who have elevated in T helper ( T h1)/ T h2 cytokine producing cell ratios. Method of study This was a prospective cohort study of treatment for RIF patients ( n = 42) with elevated peripheral blood T h1 ( CD 4 + / IFN ‐γ + )/ T h2 ( CD 4 + / IL ‐4 + ) cell ratios at the Sugiyama clinic between November 2011 and October 2013. Twenty‐five patients were treated with tacrolimus (treatment group) and 17 received no treatment (control group). Treatment group received tacrolimus 2 days before embryo transfer and continued until the day of the pregnancy test, for a total of 16 days. The daily dose of tacrolimus (1–3 mg) was determined based on the degree of the T h1/ T h2 cell ratio. Results The clinical pregnancy rate of the treatment group was 64.0%, which was significantly higher than that of the control group (0%) ( P < 0.0001). In the treatment group, the miscarriage rate was 6.3%, the live birthrate was 60.0% ( P < 0.0001). There was no significant side‐effect from tacrolimus in treatment group. No one developed obstetrical complications during pregnancy. Conclusion An immunosuppressive treatment using tacrolimus improved pregnancy outcome of repeated implantation failure patients with elevated T h1/ T h2 ratios.